Myrtol Standardized

Metadata

Approved Indications

Regulatory Status

• Registered as a phytopharmaceutical in Germany and many European and non-European countries
• Classified as a defined combination of essential oil components
• Not a single-herb product; therefore does not have a classical Commission E monograph in the traditional sense, but is approved through the German drug registration process

Approved For

• Acute and chronic inflammatory diseases of the respiratory tract
• Acute sinusitis / rhinosinusitis
• Acute bronchitis
• Chronic bronchitis (supportive)

EMA/HMPC

• Well-established in the treatment of acute and chronic inflammatory diseases of the respiratory tract, particularly sinusitis and bronchitis

Agreement/Disagreement

Consistent approval across German and European regulatory frameworks for both sinusitis and bronchitis. The dual indication (upper and lower airways) is a distinctive feature.

Conditions Treated

• Acute sinusitis / rhinosinusitis (primary)
• Acute bronchitis (primary)
• Chronic bronchitis (supportive)
• Chronic rhinosinusitis (emerging evidence)
• COPD (adjunctive, emerging)
• Cystic fibrosis (limited evidence for mucolytic effect on sputum)

Mechanism of Action

ELOM-080 has a multi-target mechanism reflecting the combined pharmacology of its three principal monoterpenes:

1. Secretolytic / Mucolytic

• Reduces viscoelasticity of mucus (sputum) by approximately 10-16% in vitro
• This reduction is comparable to N-acetylcysteine (NAC)
• Tested on sputum from patients with bronchial asthma, chronic bronchitis, and cystic fibrosis
• Stimulates serous secretion in bronchial glands (secretolytic)

2. Secretomotoric (Mucociliary Clearance)

• Increases ciliary beat frequency
• Enhances mucociliary transport velocity
• Promotes physical clearance of mucus from the airways and sinuses

3. Anti-inflammatory

• Inhibits 5-lipoxygenase (5-LOX) activity in basophil and eosinophil leukocytes
• Reduces leukotriene C4 (LTC4) formation
• Suppresses pro-inflammatory cytokine production
• Antioxidative effects: scavenges reactive oxygen species

4. Antimicrobial

• Broad-spectrum antibacterial activity in vitro
• Contributes to resolution of secondary bacterial infections in sinusitis and bronchitis

5. Bronchospasmolytic

• Mild bronchodilatory effect
• Complements the secretolytic and anti-inflammatory actions

Pharmacokinetic Note

• ELOM-080 is formulated as enteric-coated (gastroresistant) soft capsules
• Coating ensures release in the small intestine, avoiding gastric degradation
• Absorption occurs in the intestine; monoterpenes are then partially excreted via the lungs, providing direct airway exposure
• This pulmonary excretion pathway is pharmacologically significant: the active compounds reach the airways both systemically and locally via expiration

Clinical Evidence Summary

Acute Bronchitis

Matthys et al. (2000) — Landmark Head-to-Head Trial

• Design: Multicenter, randomized, double-blind, placebo-controlled with active comparators
• Population: Patients with acute bronchitis
• Arms: Myrtol standardized (4 x 300 mg/day) vs. cefuroxime (antibiotic) vs. ambroxol (mucolytic) vs. placebo
• Duration: 14 days
• Results:
  • All three active treatments superior to placebo
  • Myrtol standardized showed comparable efficacy to cefuroxime (an antibiotic) and ambroxol
  • Good tolerability across all groups
• Significance: Demonstrates a herbal product with efficacy comparable to an antibiotic for acute bronchitis
• [Source: PubMed 10994153]

Gillissen et al. (2013) — Placebo-Controlled RCT

• Design: Multicenter, randomized, double-blind, placebo-controlled
• Population: Adults with acute bronchitis
• Intervention: GeloMyrtol forte vs. placebo
• Results: Superior efficacy of GeloMyrtol forte over placebo
• [Source: PubMed 23447044]

Acute Sinusitis

Federspil et al. (1997) — RCT in Acute Sinusitis

• Design: Multicenter, randomized, double-blind, placebo-controlled
• Population: 331 patients with uncomplicated non-purulent acute sinusitis
• Intervention: Myrtol standardized vs. placebo for 1 week
• Results: Myrtol superior to placebo in acute sinusitis symptom reduction

Chronic Rhinosinusitis

Long-term CT Study

• After 3 months of GeloMyrtol forte treatment
• Significantly lower Lund-Mackay CT scores in the treatment group compared to placebo
• Radiological improvement documented on computed tomography
• [NEEDS-RESEARCH: Full study details and sample size]

Pediatric Evidence

• Post-marketing surveillance study in children: Myrtol standardized is safe and effective in treating acute and chronic respiratory infections in children
• [Source: PubMed 9825116]

Systematic Review (2025)

• A rapid review of clinical studies confirmed effectiveness and safety of GeloMyrtol forte in acute and chronic bronchitis
• [Source: ScienceDirect, 2025]

European vs. US/Anglophone Consensus

Notable: The head-to-head comparison with cefuroxime showing comparable efficacy makes this one of the most compelling cases for herbal respiratory medicine. This evidence has not penetrated Anglophone medical consciousness.

Safety Profile

Contraindications

• Hypersensitivity to eucalyptus oil, sweet orange oil, myrtle oil, lemon oil, cineole, or any excipient
• Inflammatory disorders of the stomach, intestines, or bile ducts
• Severe liver disease
• Children under 6 years (GeloMyrtol forte 300 mg capsules)

Drug Interactions

• No known clinically significant drug interactions
• Theoretical CYP enzyme induction potential (monoterpenes); clinical relevance not established
• [NEEDS-RESEARCH: Formal drug interaction studies]

Side Effects

• Gastrointestinal (uncommon): Stomach pain, upper abdominal discomfort, taste changes
• GI (rare): Nausea, vomiting, diarrhea
• Other (rare): Kidney/gallstone movement may occur (due to spasmolytic effects on smooth muscle)
• Allergic reactions: Rare
• Side effects are generally mild and resolve spontaneously

Pregnancy and Lactation

• Pregnancy: Not recommended due to insufficient safety data
• Lactation: Not recommended; volatile terpenes may pass into breast milk

Clinical Dosage

GeloMyrtol forte (300 mg ELOM-080 per capsule) — Adults and Adolescents 12+

GeloMyrtol / Myrtol (120 mg) — Children 6-12 years

Administration

• Take 30 minutes before meals with plenty of cold liquid
• Enteric-coated capsules should be swallowed whole, not chewed or crushed
• Cold liquid is important to prevent premature dissolution of the enteric coating

Sources

• ELOM-080 Wikipedia article (comprehensive pharmaceutical overview)
• Matthys et al. (2000). PubMed 10994153.
• Gillissen et al. (2013). PubMed 23447044.
• Federspil et al. (1997). Clinical trial in acute sinusitis.
• ScienceDirect (2025): Rapid review of GeloMyrtol forte.
• PMC 5214559: “Is Myrtol Standardized a New Alternative toward Antibiotics?”
• Pohl-Boskamp: Product information.
• Pillintrip: GeloMyrtol forte uses and dosage.
• GeloMyrtol forte Estonian PIL (patient information leaflet).
• PMC 7360323: Protocol for systematic review on myrtol in chronic bronchitis/COPD.

Connections

• Shares 1,8-cineole component with Eucalyptus (but in defined combination rather than as isolated compound)
• Compare sinusitis evidence with Primrose Cowslip (Sinupret)
• Compare bronchitis evidence with Pelargonium Sidoides and Ivy Leaf